German fine chemical startup BIOWEG is reported to be building what is described as Europe’s largest bacterial cellulose production plant in Elsdorf, North Rhine-Westphalia, Germany. The company is reported to have raised approximately €35 million (around $40.6 million) in funding, combining equity investment and EU grants, to finance the project.
The plant is to be built within an existing sugar industry complex, and is reported to employ precision fermentation technology using molasses as a fermentation feedstock. The bacterial cellulose produced is a biodegradable biopolymer material; a separate EPC contractor has not been disclosed.
Total funds raised amount to €35 million (approximately $40.6 million), and the plant’s annual production capacity is reported at up to 10,000 tonnes. Construction is scheduled to begin in the fourth quarter of 2026, with commercial production targeted to start in 2028, according to reports.
The investment is reported to represent an attempt to diversify into precision fermentation-based biomaterial production by leveraging existing sugar industry infrastructure, aimed at addressing growing European demand for plastic substitute materials.
This project illustrates how biopolymer production using precision fermentation technology in Europe is expanding into a new fine chemical business model by combining with existing sugar and agricultural infrastructure. Locating the plant within a sugar industry complex, rather than a conventional chemical plant, offers advantages in sourcing feedstock (molasses) and reusing existing fermentation infrastructure, which could be cited as a site-selection strategy for other biomaterial startups going forward. Bacterial cellulose is drawing attention as a plastic substitute across various applications including packaging and medical materials, and should this plant succeed in commercialization, it could secure a leading position in the related market, according to observers. The involvement of EU grant funding indicates that the European Union is providing policy support to build domestic production capacity in fine chemicals and biomaterials, which some view as potentially leading to further support for similar projects going forward. However, as there are still relatively few cases of large-scale commercialization of nascent precision fermentation technology, the actual operational performance of this project is likely to serve as an important reference point for the industry.
Whether construction scheduled for the fourth quarter of 2026 proceeds as planned, and whether the 2028 commercial production target is achieved without disruption, are primary points to watch. Whether the precision fermentation process can maintain laboratory-level yield and quality at large-scale production is also worth monitoring. In addition, which applications — packaging or medical materials — will receive priority supply of the bacterial cellulose produced, and whether additional investment or capacity expansion plans emerge following this funding round, bear watching.